Supernus to Present at Two November Investor Conferences Read more about Supernus to Present at Two November Investor Conferences
Supernus Provides Regulatory Updates for SPN-812 and SPN-830 Read more about Supernus Provides Regulatory Updates for SPN-812 and SPN-830
Supernus Announces Third Quarter 2020 Financial Results Read more about Supernus Announces Third Quarter 2020 Financial Results
Supernus to Host Third Quarter 2020 Financial Results Conference Call Read more about Supernus to Host Third Quarter 2020 Financial Results Conference Call
Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer Read more about Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer
Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two Treatments Read more about Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two Treatments
Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference Read more about Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Supernus to Present at the Wells Fargo Virtual Health Care Conference Read more about Supernus to Present at the Wells Fargo Virtual Health Care Conference
Supernus Announces Second Quarter 2020 Financial Results Read more about Supernus Announces Second Quarter 2020 Financial Results
Supernus Announces Preliminary Second Quarter 2020 Revenue Read more about Supernus Announces Preliminary Second Quarter 2020 Revenue